Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Checkpoint Therapeutics Inc (CKPT)

Checkpoint Therapeutics Inc (CKPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,567
  • Shares Outstanding, K 48,833
  • Annual Sales, $ 100 K
  • Annual Income, $ -51,850 K
  • EBIT $ -35 M
  • EBITDA $ -35 M
  • 60-Month Beta 1.34
  • Price/Sales 1,692.56
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 196.86% ( -72.21%)
  • Historical Volatility 83.62%
  • IV Percentile 77%
  • IV Rank 26.00%
  • IV High 640.26% on 04/29/24
  • IV Low 41.08% on 10/03/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 2,465
  • Volume Avg (30-Day) 2,029
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 31,972
  • Open Int (30-Day) 19,178

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -1.10
  • Growth Rate Est. (year over year) +80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +25.84%
on 12/17/24
4.50 -16.67%
on 12/02/24
+0.37 (+10.95%)
since 11/20/24
3-Month
2.14 +75.23%
on 09/26/24
4.50 -16.67%
on 12/02/24
+1.34 (+55.60%)
since 09/20/24
52-Week
1.38 +171.74%
on 05/01/24
4.50 -16.67%
on 12/02/24
+1.99 (+113.07%)
since 12/20/23

Most Recent Stories

More News
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
LLY : 767.76 (+1.35%)
ONC.TO : 1.19 (-9.16%)
OSTX : 3.97 (+1.53%)
CRDF : 4.26 (-5.12%)
FDA Approves Checkpoint Therapeutics' UNLOXCYTâ„¢ for Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics announces FDA approval of UNLOXCYTâ„¢ for treating advanced cutaneous squamous cell carcinoma in non-surgical patients.Quiver AI SummaryCheckpoint Therapeutics, Inc. announced that...

CKPT : 3.75 (+11.28%)
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

FBIO : 1.7200 (-1.15%)
CKPT : 3.75 (+11.28%)
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/CNW/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among people under...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
RCUS : 15.50 (+0.26%)
BCTX : 0.5610 (-4.12%)
ONC.TO : 1.19 (-9.16%)
AKYA : 2.49 (-2.35%)
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
RCUS : 15.50 (+0.26%)
BCTX : 0.5610 (-4.12%)
AKYA : 2.49 (-2.35%)
ONC.TO : 1.19 (-9.16%)
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FBIO : 1.7200 (-1.15%)
CKPT : 3.75 (+11.28%)
10 Stocks Retailers On Stocktwits Are Most Bullish/Bearish About To Start The Week

As the new week unfolds, earnings and economic data will again dictate sentiment.

MARA : 19.96 (-2.01%)
BLK : 1,028.69 (+1.22%)
NFLX : 909.05 (+0.78%)
PDD : 99.51 (-1.48%)
AUPH : 9.03 (-0.11%)
CKPT : 3.75 (+11.28%)
EVH : 11.41 (+2.06%)
EBS : 8.10 (+0.50%)
BIDU : 85.80 (+0.26%)
SPY : 591.15 (+1.20%)
COIN : 278.71 (+1.75%)
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimabPreviously met primary endpoint in...

CKPT : 3.75 (+11.28%)

Business Summary

Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New...

See More

Key Turning Points

3rd Resistance Point 4.33
2nd Resistance Point 4.04
1st Resistance Point 3.90
Last Price 3.75
1st Support Level 3.47
2nd Support Level 3.18
3rd Support Level 3.04

See More

52-Week High 4.50
Last Price 3.75
Fibonacci 61.8% 3.31
Fibonacci 50% 2.94
Fibonacci 38.2% 2.57
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar